125 related articles for article (PubMed ID: 22759092)
1. Endocrine therapy in DCIS: how do we proceed?
Dixon JM; Jane Macaskill E
Breast J; 2012; 18(4):295-8. PubMed ID: 22759092
[No Abstract] [Full Text] [Related]
2. Postmenopausal women with DCIS post-mastectomy: a potential role for aromatase inhibitors.
Chlebowski RT; Col N
Breast J; 2012; 18(4):299-302. PubMed ID: 22681627
[TBL] [Abstract][Full Text] [Related]
3. COX-2 expression is predictive for early relapse and aromatase inhibitor resistance in patients with ductal carcinoma in situ of the breast, and is a target for treatment.
Generali D; Buffa FM; Deb S; Cummings M; Reid LE; Taylor M; Andreis D; Allevi G; Ferrero G; Byrne D; Martinotti M; Bottini A; Harris AL; Lakhani SR; Fox SB
Br J Cancer; 2014 Jul; 111(1):46-54. PubMed ID: 24874483
[TBL] [Abstract][Full Text] [Related]
4. Is it rational to extend the duration of preventive endocrine treatment in hormone receptor positive ductal carcinoma in situ?
Altundag K
J BUON; 2018; 23(3):835. PubMed ID: 30003760
[No Abstract] [Full Text] [Related]
5. [New results of endocrine therapy of breast cancer (the role of Aromasin)].
Semiglazov VF; Semiglazov VV; Klemtsel' AA; Barash NIu; Zhil'tsova EK; Bozhok AA; Mel'nikova OA; Paltuev RM; Dashian GA; PetrovskiÄ SG; Ivanov VG; Tonuzov EE; Berstein LM
Vopr Onkol; 2004; 50(6):729-36. PubMed ID: 15755074
[No Abstract] [Full Text] [Related]
6. Deep time: the long and the short of adjuvant endocrine therapy for breast cancer.
Burstein HJ; Griggs JJ
J Clin Oncol; 2012 Mar; 30(7):684-6. PubMed ID: 22271478
[No Abstract] [Full Text] [Related]
7. The role of aromatase inhibitors in the management of ductal carcinoma in situ with an estrogen receptor-positive/progesterone receptor-negative/Her-2/neu receptor-positive pattern.
Altundag K; Bulut N; Sari E; Harputluoglu H
Am J Surg; 2007 Aug; 194(2):272-3. PubMed ID: 17618822
[No Abstract] [Full Text] [Related]
8. Exemestane or tamoxifen?
Atkins CD
Lancet; 2007 May; 369(9573):1600; author reply 1600-1. PubMed ID: 17499597
[No Abstract] [Full Text] [Related]
9. Switching to aromatase inhibitors in early breast cancer.
Boccardo F; Rubagotti A
Lancet; 2007 Feb; 369(9561):533-5. PubMed ID: 17307082
[No Abstract] [Full Text] [Related]
10. [Advancement in endocrine therapy for breast cancer].
Yang MT; Lian ZQ
Ai Zheng; 2007 Apr; 26(4):440-4. PubMed ID: 17430670
[TBL] [Abstract][Full Text] [Related]
11. Adjuvant ovarian suppression in premenopausal breast cancer.
Montemurro F; Perrone F; Geuna E
N Engl J Med; 2015 Apr; 372(17):1672-3. PubMed ID: 25901438
[No Abstract] [Full Text] [Related]
12. Adjuvant ovarian suppression in premenopausal breast cancer.
Francis PA; Regan MM; Fleming GF
N Engl J Med; 2015 Apr; 372(17):1673. PubMed ID: 25901437
[No Abstract] [Full Text] [Related]
13. Exemestane or tamoxifen?
Ueda M; Toji E; Noda S
Lancet; 2007 May; 369(9573):1600; author reply 1600-1. PubMed ID: 17499595
[No Abstract] [Full Text] [Related]
14. Update: a 62-year-old woman with a new diagnosis of breast cancer.
Farag N; Burns R; Come SE
JAMA; 2008 Mar; 299(9):1055-6. PubMed ID: 18319415
[No Abstract] [Full Text] [Related]
15. Perfecting breast-cancer treatment--incremental gains and musculoskeletal pains.
Hershman DL
N Engl J Med; 2015 Jan; 372(5):477-8. PubMed ID: 25495491
[No Abstract] [Full Text] [Related]
16. Adjuvant aromatase inhibitor therapy for early breast cancer: A review of the most recent data.
Grana G
J Surg Oncol; 2006 Jun; 93(7):585-92. PubMed ID: 16705732
[TBL] [Abstract][Full Text] [Related]
17. Cancer: some reasons to be hopeful.
Lancet; 2007 Feb; 369(9561):531. PubMed ID: 17307079
[No Abstract] [Full Text] [Related]
18. Radiation beats tamoxifen after DCIS treatment.
Health News; 2003 Sep; 9(9):8. PubMed ID: 14584475
[No Abstract] [Full Text] [Related]
19. Neoadjuvant hormonal therapy for ductal carcinoma in situ: trial design and preliminary results.
Hwang ES; Esserman L
Ann Surg Oncol; 2004 Jan; 11(1 Suppl):37S-43S. PubMed ID: 15015708
[TBL] [Abstract][Full Text] [Related]
20. Controversies in endocrine treatment: effective utilization of steroidal and nonsteroidal aromatase inhibitors: now and in the future. Forward.
Aapro M
Anticancer Drugs; 2008 Mar; 19 Suppl 2():S1. PubMed ID: 18337639
[No Abstract] [Full Text] [Related]
[Next] [New Search]